학술논문

Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial
Document Type
Article
Source
In: The Lancet. (The Lancet, 29 July 2023, 402(10399):373-385)
Subject
Language
English
ISSN
1474547X
01406736